GB0612326D0 - Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms - Google Patents

Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms

Info

Publication number
GB0612326D0
GB0612326D0 GBGB0612326.9A GB0612326A GB0612326D0 GB 0612326 D0 GB0612326 D0 GB 0612326D0 GB 0612326 A GB0612326 A GB 0612326A GB 0612326 D0 GB0612326 D0 GB 0612326D0
Authority
GB
United Kingdom
Prior art keywords
methods
dosage forms
sustained release
oral dosage
release oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0612326.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of GB0612326D0 publication Critical patent/GB0612326D0/en
Priority to GB0616703A priority Critical patent/GB2431875A/en
Priority to EP06254394A priority patent/EP1849460A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB0612326.9A 2005-10-31 2006-06-21 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms Ceased GB0612326D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0616703A GB2431875A (en) 2005-10-31 2006-08-22 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
EP06254394A EP1849460A3 (en) 2005-10-31 2006-08-22 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73199505P 2005-10-31 2005-10-31
US80201706P 2006-05-18 2006-05-18

Publications (1)

Publication Number Publication Date
GB0612326D0 true GB0612326D0 (en) 2006-08-02

Family

ID=36758362

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0612326.9A Ceased GB0612326D0 (en) 2005-10-31 2006-06-21 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms

Country Status (11)

Country Link
BG (1) BG1070U1 (sv)
CA (6) CA2554874A1 (sv)
CZ (1) CZ19137U1 (sv)
DK (1) DK200600189U3 (sv)
FI (1) FI7357U1 (sv)
GB (1) GB0612326D0 (sv)
IE (1) IES20060507A2 (sv)
NL (1) NL1032148C1 (sv)
NO (1) NO20063233L (sv)
SE (1) SE0601589L (sv)
SK (1) SK5202Y1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5965583B2 (ja) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
TWI679012B (zh) * 2015-09-11 2019-12-11 法德生技藥品股份有限公司 含有達方吡啶的緩釋口服滲透錠劑及其用途

Also Published As

Publication number Publication date
NL1032148C1 (nl) 2006-11-17
NO20063233L (no) 2007-05-02
CA2554693A1 (en) 2007-04-30
IES20060507A2 (en) 2007-05-30
CA2554874A1 (en) 2007-04-30
CA2554698A1 (en) 2007-04-30
SK5202Y1 (en) 2009-06-05
CA2554701A1 (en) 2007-04-30
SK50572006U1 (en) 2009-01-07
CZ19137U1 (cs) 2008-12-08
FIU20060296U0 (sv) 2006-07-12
FI7357U1 (sv) 2007-01-16
CA2554697A1 (en) 2007-04-30
CA2554684A1 (en) 2007-04-30
BG1070U1 (bg) 2008-06-30
DK200600189U3 (da) 2007-02-23
SE0601589L (sv) 2007-05-01

Similar Documents

Publication Publication Date Title
HK1106451A1 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
IL268462A (en) Dosage form of risedronate
ZA200703571B (en) Gabapentin prodrug sustained release oral dosage forms
PT2046298T (pt) Forma de dosagem farmacêutica contendo uma composição solubilizante farmaceuticamente aceitável
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
IL194277A0 (en) Solid oral dosage form containing an enhancer
EP2040731A4 (en) SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
PL2077729T3 (pl) Doustne postacie dawkowania probiotyku
IL193727A0 (en) Dosage forms for administering combinations of drugs
EP1750674A4 (en) MICROPARTICLES FOR THE ORAL LEVY
PL2457562T3 (pl) Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego
IL188313A0 (en) Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
SI1906961T1 (sl) Trdne farmacevtske formulacije fentanila z izboljšano bukalno absorpcijo
IL184656A0 (en) Dosage form and method for sustained release of a substituted pyrazine compound
IL177402A0 (en) Composition for oral administration of tamsulosin hydrochloride
ZA200610770B (en) Dosage form for delivery of multiple drug forms
IL179992A0 (en) Immediate release formulations of memantine oral dosage forms
GB0616703D0 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
GB0612326D0 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
EP1765340A4 (en) COMPOSITION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION OF NIACIN
ZA200804734B (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
GB0403808D0 (en) Films for use as dosage forms
EP1932923A4 (en) METHOD FOR DETERMINING AN EFFECTIVE DOSE OF METHOTREXATE
SE0602280L (sv) Förfaranden för minskning av alkoholinducerad dosdumpning för orala opioiddosformer med fördröjt frisättande
IL202272A0 (en) Process for forming solid oral dosage forms of angiotensin ii receptor antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)